Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
An announcement from Tonix Pharma ( (TNXP) ) is now available.
On February 3, 2025, Tonix Pharmaceuticals terminated a Loan Agreement by paying off $9.6 million, which included a prepayment fee. Additionally, Tonix’s Board approved a 1-for-100 reverse stock split to meet NASDAQ’s minimum bid price requirement for continued listing, effective February 5, 2025. This strategic move aims to stabilize Tonix’s market position, ensuring compliance with NASDAQ rules and potentially affecting the stockholders’ equity structure due to changes in share count.
More about Tonix Pharma
Tonix Pharmaceuticals Holding Corp., a Nevada corporation, operates in the pharmaceutical industry with a focus on developing therapies for central nervous system disorders, immunology, and infectious diseases. The company is known for its research-driven approach and has multiple subsidiaries, including Tonix Pharmaceuticals, Inc., Krele LLC, Jenner Institute, LLC, and Tonix R&D Center, LLC.
YTD Price Performance: 36.31%
Average Trading Volume: 129,840,551
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $80.01M
For an in-depth examination of TNXP stock, go to TipRanks’ Stock Analysis page.
